Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

296
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
296
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

132
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
132
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

798
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
798

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial.

Annals of the American Thoracic Society·2026
Same author

Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE Study.

Pulmonary therapy·2025
Same author

Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Frontiers in immunology·2024
Same author

Executive Summary: State-of-the-Art Review: Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Analysis of alpha-1-antitrypsin (AAT)-regulated, glucocorticoid receptor-dependent genes in macrophages reveals a novel host defense function of AAT.

Physiological reports·2024

Related Experiment Video

Updated: May 28, 2025

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos
10:38

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos

Published on: September 9, 2015

10.1K

Mycobacterium abscessus group pulmonary disease.

David E Griffith1

  • 1Division of Mycobacterial Disease and Lung Infections, Department of Medicine, National Jewish Health, Denver, Colorado, USA.

Current Opinion in Infectious Diseases
|February 10, 2025
PubMed
Summary

Mycobacterium abscessus pulmonary disease is difficult to treat due to drug resistance. Optimizing therapies and exploring new treatments like phage therapy are crucial for better outcomes in managing this nontuberculous mycobacterial infection.

More Related Videos

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
05:40

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

562
Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes
08:34

Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes

Published on: September 27, 2018

8.5K

Related Experiment Videos

Last Updated: May 28, 2025

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos
10:38

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos

Published on: September 9, 2015

10.1K
Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
05:40

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

562
Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes
08:34

Identification of Virulence Markers of Mycobacterium abscessus for Intracellular Replication in Phagocytes

Published on: September 27, 2018

8.5K

Area of Science:

  • Infectious Diseases
  • Pulmonary Medicine
  • Microbiology

Background:

  • Mycobacterium abscessus is a significant respiratory pathogen.
  • It is recognized as one of the most challenging nontuberculous mycobacterial (NTM) infections to treat.
  • Pulmonary disease caused by M. abscessus requires careful management strategies.

Purpose of the Study:

  • To review current management strategies for M. abscessus pulmonary disease.
  • To identify opportunities and limitations in treating this infection.
  • To guide therapy optimization and avoid treatment choices that complicate patient management.

Main Methods:

  • Literature review focusing on M. abscessus drug resistance mechanisms.
  • Analysis of in-vitro susceptibility testing limitations.
  • Discussion of treatment outcomes based on macrolide susceptibility.

Main Results:

  • Drug resistance in M. abscessus significantly impacts treatment response.
  • Macrolide resistance is a key factor differentiating treatment outcomes.
  • Current in-vitro susceptibility testing has limitations for M. abscessus isolates.
  • Favorable outcomes for M. abscessus pulmonary disease remain challenging to achieve.

Conclusions:

  • Effective treatment outcomes for M. abscessus pulmonary disease are not yet predictable.
  • Novel antibiotic combinations show potential but require extensive clinical trials.
  • Emerging therapies like phage therapy are not yet widely available or consistently effective.
  • Current treatment strategies are imperfect, necessitating further research for improved patient care.